In 2018, the TOZURA study evaluated the efficacy and safety of TCZ-SC as monotherapy or in combination with csDMARDs in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve. The gene discussed is TNF; the disease is rheumatoid arthritis.